Theratechnologies Inc. Common - THTX STOCK NEWS

Theratechnologies (THTX) reported record revenues of $19.1 million for Q4 and $66.1 million for FY2020. The company saw significant growth in net sales, driven by its HIV treatment portfolio, especially EGRIFTA which recorded a 23.1% increase. Trogarzo also showed a 9.2% rise in sales. R&D expenses rose to $18 million, reflecting ongoing clinical developments, including Phase 3 trials for NASH and Phase 1 for TH1902. Despite revenue growth, a net loss of $22.7 million for FY2020 was reported, primarily due to higher operational expenses.

Theratechnologies Inc. (THTX) will release its financial results for the fourth quarter and fiscal year ending November 30, 2020, on February 25, 2021. A conference call is scheduled for the same day at 8:30 a.m. (ET) to discuss these results, hosted by CEO Paul Lévesque. Participants can join via toll-free or international dialing, and a webcast will also be available. An audio replay of the call will be accessible later that day. The company focuses on developing innovative therapies for unmet medical needs.

Theratechnologies (THTX) announced that the FDA has granted fast track designation for TH1902, aimed at treating sortilin positive advanced solid tumors resistant to standard therapies. This status signifies early recognition of TH1902's potential, which addresses significant medical needs. The Phase 1 trial is set to begin in Q2 2021 to assess safety and anti-tumor activity, particularly for cancers like endometrial and triple negative breast cancer, where sortilin receptor expression is noted in 40-90% of cases. The development is supported by a $1.4 million contribution from the Canadian Cancer Society and the Quebec government.

Theratechnologies has successfully closed its bought-deal public offering, issuing 16,727,900 units at US$2.75 per unit, totaling US$46 million in gross proceeds. The offering included an over-allotment option, accounting for 2,181,900 additional units.

Each unit consists of one common share and half a warrant, exercisable until January 19, 2024, at US$3.18 per share. Proceeds will fund research, commercialization initiatives, and other corporate purposes.

Theratechnologies (NASDAQ: THTX) announced that CEO Paul Levesque and CMO Dr. Christian Marsolais will present at the B. Riley Virtual Oncology Investor Conference on January 20, 2021, at 3:30 p.m. ET. The presentation will focus on the company's innovative therapies aimed at addressing unmet medical needs. Interested parties can access the live virtual presentation through the company's website's 'News' section, with a replay available two hours later. For more information, visit theratech.com.

Theratechnologies has announced an agreement with Canadian underwriters to sell 14,546,000 units at US$2.75 per unit, raising approximately US$40 million. Each unit comprises one common share and one-half warrant, with a three-year exercise price of US$3.18. The offering's net proceeds will mainly support research and development, commercialization, and general corporate needs. Closing is expected around January 19, 2021, subject to regulatory approvals, including Toronto Stock Exchange listing.

Theratechnologies (THTX) expects record revenues for Q4 and FY 2020, estimating between $18.9 million and $19.2 million for Q4, a rise of 15% to 17%, and $65.8 million to $66.1 million for FY 2020, up 4.1% to 4.6%. The company received FDA approval for Phase 3 trials of tesamorelin in NASH and Phase 1 trials for TH1902 in various cancers. The Phase 3 trial for tesamorelin aims to enroll 2,000 participants and is set to start in Q3 2021, while the TH1902 trial is planned to initiate in Q2 2021.

Theratechnologies (NASDAQ: THTX) has announced promising pre-clinical findings for TH1902, a novel peptide-drug conjugate targeting SORT1+ cancers. New results show TH1902's efficacy in colorectal, pancreatic, melanoma, and endometrial cancers, building on earlier findings in ovarian and triple-negative breast cancers. Importantly, toxicity studies confirm TH1902 can be administered at three times the maximum tolerated dose of docetaxel, suggesting a potentially improved safety profile. These findings herald a significant step forward for treatments targeting hard-to-treat cancers.

MONTREAL, Nov. 23, 2020 – Theratechnologies (TSX: TH, NASDAQ: THTX) announced participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1-2, 2020. Paul Levesque, President and CEO, will be featured in a pre-recorded fireside chat available for online viewing. Interested parties can access the chat via the company's website. Theratechnologies is dedicated to developing innovative therapies for unmet medical needs. For more details, visit www.theratech.com.